Presbia plc01.20.16
Dublin, Ireland-based Presbia plc, an ophthalmic device company and leader in near-vision restoration, announced today that it has appointed Gerald Farrell, Ph.D. to serve on its board of directors and as a member of its audit committee.
Farrell has been involved in the pharmaceutical industry for more than 25 years, and worked for Eli Lilly Company Limited in Ireland and the United Kingdom for the majority of his successful career. Dr. Farrell’s tenure at Eli Lilly included positions of managing director, leading the commercial sales and marketing in Ireland where he launched several major products in Europe; director strategy, commercial and business in the United Kingdom accountable for long-term strategic planning and business operations as well as other positions related to compliance, production, sales, and planning.
“Presbia will benefit from Gerald’s experience and success in consumer-oriented healthcare, and building organizations and teams across countries as we execute our strategic commercial roll out in both Asia and Europe,” said Randy Thurman, executive chairman of Presbia. “He will be joining a strong group of directors and officers leading the company as Presbia continues to execute its goal of being the best solution for presbyopia, an affliction that affects 1.8 billion people worldwide.”
Farrell earned a Ph.D. plant biotechnology from University College, Cork, and a B.Sc. honors – plant science and higher diploma education with honors from University College, Galway. He serves on the board for UCD Michael Smurfit Graduate Business School, serves as a director, and previously served as president, for Irish Pharmaceutical Healthcare Association, and serves as a council member for the Dublin Chamber of Commerce. Previously, from 2003 until 2014, Farrell served as a director of Eli Lilly and Company (Ireland) Ltd.
Farrell has been involved in the pharmaceutical industry for more than 25 years, and worked for Eli Lilly Company Limited in Ireland and the United Kingdom for the majority of his successful career. Dr. Farrell’s tenure at Eli Lilly included positions of managing director, leading the commercial sales and marketing in Ireland where he launched several major products in Europe; director strategy, commercial and business in the United Kingdom accountable for long-term strategic planning and business operations as well as other positions related to compliance, production, sales, and planning.
“Presbia will benefit from Gerald’s experience and success in consumer-oriented healthcare, and building organizations and teams across countries as we execute our strategic commercial roll out in both Asia and Europe,” said Randy Thurman, executive chairman of Presbia. “He will be joining a strong group of directors and officers leading the company as Presbia continues to execute its goal of being the best solution for presbyopia, an affliction that affects 1.8 billion people worldwide.”
Farrell earned a Ph.D. plant biotechnology from University College, Cork, and a B.Sc. honors – plant science and higher diploma education with honors from University College, Galway. He serves on the board for UCD Michael Smurfit Graduate Business School, serves as a director, and previously served as president, for Irish Pharmaceutical Healthcare Association, and serves as a council member for the Dublin Chamber of Commerce. Previously, from 2003 until 2014, Farrell served as a director of Eli Lilly and Company (Ireland) Ltd.